Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.